MDACC Study No:2009-0583 ( NCT No: NCT01014936)
Title:A Phase I Open-Label, Non-Randomized, Dose-Escalation
First-in-Man Trial to Investigate the c-Met Kinase Inhibitor
MSC2156119J Under Three Different Regimens in Subjects
with Advanced Solid Tumors
Principal Investigator:David S. Hong
Treatment Agent:MSC2156119J
Study Status:Closed
Study Description:The goal of this clinical research study is to find a dose and schedule of
MSC2156119J (also known as EMD 1214063) ("study drug") that can be safely given
to patients with advanced solid cancer.

How well the study drug works in the treatment of cancer will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Solid Tumors
Phase of Study:Phase I
Treatment Agents:MSC2156119J
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:EMD Serono, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:David S. Hong
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-563-1930
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults